The formation of human gonads is an exquisitely timed developmental event, occurring during embryogenesis with critical milestones set between four to six weeks post-fertilization. During this early embryonic window, the bipotential gonadal ridges differentiate into either testes or ovaries based on tightly regulated genetic and molecular cues. Studying this sex determination process has historically been fraught with complexity, hindered by its timing, ethical challenges surrounding human embryonic research, and notable species-specific differences that limit animal model extrapolation. Consequently, a complete understanding and modeling of atypical gonadal development have remained elusive, obstructing advances in diagnostics and therapeutics for DSDs.

DSDs encompass a heterogeneous group of rare conditions characterized by discordance between chromosomal sex and gonadal or anatomical sexual differentiation. Affecting approximately one in 4,500 live births, these conditions range from severe presentations detected prenatally or shortly after birth, to milder variations that may manifest at puberty or remain undiagnosed into adulthood. Despite advances in genetic sequencing over the past decade and the identification of numerous causative genes, roughly half of DSD cases with atypical gonad development still lack definitive genetic diagnoses, underscoring unmet clinical needs and the necessity for more predictive disease models.

Addressing these challenges, the research team utilized human induced pluripotent stem cells (hiPSCs), which possess the remarkable ability to differentiate into multiple cell types, to recreate key cellular constituents of the ovary. Specifically, hiPSCs were guided to become granulosa-like cells, a crucial somatic cell population responsible for nurturing maturing oocytes and supporting follicle formation. Concurrently, primordial germ cell-like cells (PGCLCs), precursors to future gametes, were generated. By co-culturing and combining these two cell populations without introducing exogenous transcription factors—which can artificially alter intrinsic genetic programs—the researchers successfully engineered complex ovarian organoids that faithfully recapitulate vital structural and functional hallmarks of human ovarian follicles.

This methodological breakthrough diverges significantly from prior models that often relied on forced expression of external transcription factors, which risk disrupting authentic developmental gene regulatory networks and limit relevance to disease modeling. According to senior author Dr. Anu Bashamboo, this endogenous differentiation strategy preserves the innate genetic programs within the cells, enhancing the fidelity and applicability of the derived populations to investigate natural ovarian development and pathology. Importantly, the functioning ovaroids exhibit critical cell-cell interactions and three-dimensional morphogenesis reflective of in vivo ovarian tissue architecture.

Complementing this advancement, collaborative work previously conducted at the Institut Pasteur and the Francis Crick Institute successfully generated hiPSC-derived somatic cells of the testis, namely Sertoli cells, which play a vital role in testicular development and are frequently implicated in DSDs. By cultivating cells carrying male sex chromosomes (XY) with genetic mutations associated with atypical testis formation, the team observed impaired formation of three-dimensional tubular structures reminiscent of seminiferous tubules, resulting in dysgenetic gonadal features analogous to human DSD phenotypes. Together, these parallel models of ovarian and testicular development establish a versatile platform for comparative analyses of gonadal biology.

The implications of these human-specific, stem cell-derived models extend far beyond basic science. They address critical limitations imposed by interspecies variation, where fundamental differences in gene regulation impede the translation of findings from animal models to humans. By enabling controlled, reproducible studies of human gonadal development, gene function, and disease mechanisms, this platform represents a transformative toolset for dissecting the molecular underpinnings of DSDs and related reproductive disorders.

Dr. Bashamboo highlights the broader significance of this research, emphasizing its capacity to bridge the divide between laboratory investigation and clinical application. The human ovaroid and testicular cell systems not only hold promise for advancing genetic diagnosis through improved modeling of previously cryptic conditions but also serve as scalable platforms for drug screening, toxicological assessment, and personalized medicine. Their utility could accelerate the development of targeted therapeutics tailored to individuals with infertility, gonadal tumors, or atypical sexual development.

Moreover, the potential for these organoids to facilitate environmental and pharmacological screenings represents a timely innovation, given increasing concerns about endocrine-disrupting chemicals and their effects on human reproductive health. By providing a physiologically relevant system, researchers can assess the impact of diverse compounds on human gonadal cells and structures in vitro, informing safer medical and environmental policies.

Looking towards the future, these stem cell-derived human gonadal models offer exciting possibilities for therapeutic interventions. With continued refinement, they may underpin regenerative strategies or novel approaches to restore or modulate gonadal function in patients affected by congenital anomalies or acquired diseases. The integration of such models within precision medicine frameworks could revolutionize fertility preservation, diagnosis, and treatment paradigms.

In summary, the development of human ovaroids from hiPSCs marks a pivotal advancement in reproductive biology research, pushing the boundaries of what can be studied and manipulated in human tissue models. It was presented at the first Joint Congress of ESPE and ESE, symbolizing a collaborative milestone in endocrine and reproductive science. With their robust and faithful recapitulation of ovarian follicular structures without exogenous genetic manipulation, these ovaroids provide a potent new avenue for unraveling developmental mysteries, improving diagnostic accuracy, and pioneering therapeutic innovations for complex gonadal conditions.

—

Subject of Research: Development of human ovary organoids (ovarioids) from induced pluripotent stem cells to model gonadal development and differences in sex development (DSDs)

Article Title: Not provided

News Publication Date: Not provided

Web References: Not provided

References: Not provided

Image Credits: European Society of Endocrinology

Keywords: Ovaries, Ovarian follicles, Reproductive system, Gonads, Testicles, Endocrine system, Endocrinology, Hormones, Cell cultures, Research methods, Laboratory procedures, Germ cells, Primordial germ cells, Differentiated cells, Pluripotent stem cells, Infertility, Ovarian tumors, Pediatrics, Diseases and disorders, Stem cell development, Sertoli cells, Stem cells

Differences in sex development denote a group of rare congenital conditions characterized by atypical development of chromosomal, gonadal, or anatomical sex. Individuals with DSD may possess a mosaic of reproductive, hormonal, and genetic features that do not conform neatly to traditional male or female classifications. This inherent biological complexity complicates the establishment of fair and inclusive categories in competitive sport, particularly in events emphasizing physical prowess such as sprinting and contact sports like rugby. Public awareness of DSD conditions has increased due in part to high-profile athletes like South African middle-distance runner Caster Semenya, whose career has drawn intense scrutiny and legal battles centered on eligibility and fairness.

The study foregrounds a nuanced, somewhat unexpected stance among female athletes: 43% perceive the participation of athletes with DSD in female categories as fair, compared to 36% who view it as unfair. This contrasts notably with earlier findings from the same research group involving transgender athletes, where 48% of female athletes believed the inclusion was unfair and 38% deemed it fair. Such a divergence underscores the complex and distinct considerations that athletes attribute to DSD and transgender participation, challenging blanket policies that treat these groups identically.

One of the most striking dimensions of the research is the ethical consensus emerging from the surveyed athletes concerning medical interventions. A sizable majority, amounting to 67%, consider it unethical to compel athletes with DSD to undergo hormonal treatment or other forms of medication solely to meet regulatory eligibility requirements. This challenges decades-long practices where governing bodies have mandated reductions in testosterone or other physiological parameters, often at significant personal and health costs to the athletes involved. The findings thus argue for a critical reevaluation of these policies through both ethical and empirical lenses.

Furthermore, the study reveals a pervasive rejection of segregated competition categories based specifically on DSD status, with an overwhelming 70% opposing the creation of separate divisions, particularly in precision-based sports. Athletes’ responses suggest that stratifying competition in this way may be perceived as stigmatizing or impractical given the rarity and variability of DSD conditions. Instead, a clear majority—82%—advocate for enhanced inclusivity efforts within existing competition structures, signaling a push toward more integrative and less divisive approaches in sports governance.

Led by Dr. Shane Heffernan of Swansea University’s Applied Sports Science Technology and Medicine Research Centre, this research builds upon prior work by incorporating direct athlete voices into a policy debate frequently dominated by medical, scientific, and juridical perspectives. The study’s cohort includes 21 world champions, 15 Olympians, among them multiple medalists, and six Paralympians, ensuring that the insights reflect the views of those at the pinnacle of competitive achievement. Their perspectives offer not only empirical value but also a mandate for sporting bodies to consider the lived experiences and ethical outlooks of athletes most impacted by these policies.

Dr. Heffernan emphasizes that while DSD athletes exhibit complex and individualized biological characteristics, there is no empirical evidence conclusively demonstrating that DSD confers an inherent athletic advantage at the elite level. The focus on a few high-profile cases has skewed policy development, often divorced from peer-reviewed scientific data. This research seeks to recalibrate the discourse by prioritizing inclusivity and fairness grounded in robust evidence and the athletes’ authentic experiences, rather than fear or anecdotal assumptions.

Complementing this perspective, Professor Alun Williams of Manchester Metropolitan University, an expert in sports genomics, highlights the significant gap in scientific knowledge regarding the biological impact of DSD. His extensive work on genetics and athletic performance elucidates that while DSD conditions involve rare and heterogeneous genetic anomalies affecting reproductive and hormonal systems, the translation of these biological factors into competitive advantage is neither straightforward nor well quantified. Williams stresses that conflating DSD athletes with transgender athletes in policy-making ignores crucial biological distinctions and presents serious ethical challenges.

The recent decision by World Athletics to merge regulations for transgender and DSD athletes has prompted criticism from many quarters, including the researchers leading this study. The athlete survey data demonstrates that high-level female athletes view these categories as fundamentally different and warranting separate consideration. Applying uniform eligibility standards risks oversimplifying complex biological and ethical realities, potentially undermining fairness and inclusivity goals simultaneously.

Beyond biology and policy, this study opens a critical debate about how the evolving understanding of sex and gender intersects with the centuries-old structure of competitive sport. Traditional binary classifications increasingly face challenges from scientific insight and social change alike. Athletes and organizations are grappling with how to honor competitive integrity while adapting to a more nuanced recognition of sex development diversity. This research contributes meaningfully to that discourse, advocating that athlete voices not be sidelined but placed at the heart of regulatory evolution.

The implications extend beyond sport itself, touching on broader societal questions concerning inclusion, identity, and the limits of medical intervention. The explicit rejection by a majority of athletes of mandated medication for eligibility foregrounds the human rights dimensions of doping-like regulations imposed on DSD athletes. By documenting a clear ethical stance, the study encourages sports governing bodies to reconcile regulatory frameworks with respect, dignity, and scientific integrity.

In conclusion, the findings presented offer a timely and critical contribution to ongoing debates in sports policy and ethics. They call on governing bodies such as World Athletics to rectify the conflation of DSD and transgender athletes in eligibility rules, acknowledging the distinct biological and social complexities involved. The call for more inclusive and scientifically grounded policies resonates strongly with the athletes who remain at the core of competitive sport. As research in this area advances, iterative dialogue incorporating athlete perspectives will be indispensable to forging equitable solutions in elite athletics.

—

Subject of Research: Athlete perceptions on eligibility and inclusion of athletes with Differences in Sex Development (DSD) in female competitive sports

Article Title: Female elite athlete perspectives highlight ethical and policy complexities in DSD athlete inclusion in sport

News Publication Date: 2024

Web References:

• European Journal of Sport Science – DOI: 10.1002/ejsc.12300
• Swansea University DATES Project: https://www.swansea.ac.uk/sport-exercise-sciences/astem/dates-project/

References:
Heffernan, S., Williams, A., Stebbings, G., & Chollier, M. (2024). Athlete perspectives on eligibility policies for athletes with differences in sex development: A European Journal of Sport Science publication.

Keywords:
Differences in sex development (DSD), elite sport, athlete eligibility, ethics in sport, female athletes, sports genomics, inclusion, hormone regulation, transgender athletes, World Athletics, sport policy, human biology